Welcome to our dedicated page for MTL Cannabis news (Ticker: MTLNF), a resource for investors and traders seeking the latest updates and insights on MTL Cannabis stock.
MTL Cannabis Corp. (MTLNF) generates news across cultivation, medical cannabis, corporate strategy and capital markets. As the parent of Montréal Medical Cannabis Inc., Abba Medix Corp., IsoCanMed Inc. and Canada House Clinics Inc., the company issues updates on its licensed production facilities, medical marketplace activities and clinic operations in Canada. News coverage often highlights its focus on craft quality cannabis products and its role in both medical and adult-use segments.
One major news theme for MTL Cannabis Corp. is its proposed acquisition by Canopy Growth Corporation under a definitive arrangement agreement. Articles related to this transaction describe the planned exchange of MTL shares for a mix of Canopy Growth shares and cash, the integration of MTL’s cultivation and post-harvest assets into Canopy Growth’s supply chain, and the expected impact on medical and adult-use cannabis markets in Canada and abroad. These reports also cover shareholder approvals, regulatory reviews and transaction milestones.
Investors and observers can also find news about MTL Cannabis Corp.’s participation in investor conferences and industry events. For example, the company has announced presentations at the Centurion One Capital Bahamas Summit, where its leadership engages with growth-focused investors through company presentations, one-on-one meetings and panel discussions.
Additional news items may include updates on brand performance for MTL Cannabis, Low Key by MTL and R’belle, developments in its medical cannabis marketplace and clinic network, and information about export channels for bulk and unbranded GACP quality cannabis. Following MTL Cannabis Corp. news helps readers understand how its cultivation operations, medical platforms and corporate transactions evolve over time.
Canopy Growth (Nasdaq: CGC; TSX: WEED) completed its acquisition of MTL Cannabis on March 16, 2026, creating Canada’s leading medical cannabis business by revenue. The deal: MTL became a wholly owned subsidiary, MTL shares to be de-listed, and consideration included 0.32 Canopy shares plus $0.144 cash per MTL share.
The transaction issued ~41.2 million Canopy shares and paid ~$18.5 million cash. Expected run-rate synergies are ~$10 million within 18 months and the combined business supports a path to positive adjusted EBITDA in fiscal 2027.
Canopy Growth (CGC) will acquire all issued and outstanding shares of MTL Cannabis in a transaction valued at approximately $125 million equity and $179 million TEV. Consideration is 0.32 Canopy Growth share plus $0.144 cash per MTL share, implying ~$0.91 per MTL share and a 45% premium to MTL’s 20-day VWAP as of December 12, 2025. MTL reported $84M TTM revenue, 51% gross margin (before fair value adjustments) and $11M operating cash flow for the trailing twelve months ended September 30, 2025. Canopy expects ~$10M of run-rate synergies within 18 months and closing is expected before end of February 2026, subject to court, shareholder and regulatory approvals.
MTL Cannabis Corp. (OTCQX: MTLNF) announced its participation in the upcoming Centurion One Capital 3rd Annual Bahamas Summit, scheduled for October 28-29, 2025 at the Rosewood Baha Mar Hotel in Nassau, Bahamas.
CEO Michael Perron will represent the company through presentations, panel discussions, and one-on-one investor meetings during this exclusive, invitation-only event. The summit brings together leading small-cap growth companies and global growth investors, running daily from 9:00 AM to 5:00 PM EDT.